2019年5月7日,

Promethera生物科學公司,全球創新者在細胞的藥物和肝髒疾病,今天宣布關閉€3970萬(JPY4.94十億)係列D融資。圓是由日本新投資者共同伊藤忠公司,誰貢獻€1000萬年1月,這個融資和新生銀行資本合作夥伴。MEDIPAL控股公司(日本),未來資產資本(韓國),家庭辦公室六個雪(盧森堡),韓國投資合作夥伴(韓國),Ci: z投資LLP(日本)加入圓以及比利時的私人投資者。Promethera現有的投資者,三井& Co .)全球投資公司(MGI)也參加了融資。所得資金將加速公司的持續HepaStem ACLF臨床項目和公司的第一個臨床試驗在納什。此外,資金將用於生產擴大,臨床項目和公司的整體運營和集團。“金融支持我們的新的和現有的投資者,以他們的經驗在細胞療法和廣泛的亞洲和全球網絡,將極大地幫助我們有效地推進世界上第一個細胞治療ACLF,納什通過臨床試驗,”約翰·Tchelingerian說Promethera博士,總裁兼首席執行官。“我們在後期的臨床試驗納什將很快啟動第一個在歐洲,預計將擴大到美國和亞洲。我們興奮地看到HepaStem的候選藥物可以改變嚴重肝病患者的生命。總的來說,我們看我們公司的轉型時期,融資使我們在一個偉大的位置來執行我們的計劃。” “Promethera has taken great steps to increase and bolster our relations and operations in Asia, and specifically in Japan and Korea, so we can benefit from the openness to stem-cell therapeutics in this area of the world,” said Mutsuki Takano, Group CFO and General Manager of Promethera’s Japan branch. “This territorial move has already started showing results, with our shareholder base growing significantly in Asia not least through this financing round.” HepaStem consists of liver stem cells that are obtained from ethically donated healthy human livers and expanded under cGMP conditions in production. The product candidate is currently being evaluated in a phase 2a clinical trial in the indication ACLF with first safety and efficacy results being presented recently at The International Liver Congress 2019 (EASL) as part of a late-breaking oral presentation. In addition to its cell-based approaches, HepaStem and H2Stem, Promethera is advancing a portfolio of complementary biologics approaches including the anti-TNF-R1 antibody Atrosimab. About Promethera Biosciences Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline (HepaStem and H2Stem), we develop antibody technologies such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland). Promethera®, HepaStem®, H2stem® are all registered trademarks of the PROMETHERA group. View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005807/en/ Promethera Biosciences SA